查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年化疗治疗的市场预测：按药物、药物途径、适应症、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383368

到 2030 年化疗治疗的市场预测：按药物、药物途径、适应症、最终用户和地区进行的全球分析

Chemotherapy Treatment Market Forecasts to 2030 - Global Analysis By Drug (Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Alkylating Agents, Mitotic Inhibitors, Antimetabolites and Other Drugs), Route of Drug, Dose, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球化疗治疗市场规模为 88.1 亿美元，预计预测期内复合年增长率为 9.5%，到 2030 年将达到 166.2 亿美元。

化疗是一种使用药物消除体内癌细胞或减缓其发展的医疗程序。化疗是典型的癌症治疗方法，可单独使用或与手术、放射线治疗和免疫疗法等其他治疗方法合併使用。化疗药物针对快速分裂的细胞，包括癌细胞和一些健康细胞。不幸的是，正常、健康的细胞也会受到治疗的影响，这可能导致各种负面影响，包括噁心、脱髮、疲劳和免疫力下降。

根据国际癌症研究机构提供的2021年资料，2020年欧洲地区癌症患者人数为479万人，预计2040年将增加至607万人。

癌症盛行率增加

癌症发生率在国际上迅速增加，已超过心血管疾病，成为第二大死因。化疗是最常见的癌症治疗方法，通常与其他抗癌药物合併使用。辅助化疗是在手术或放疗后用于减少癌细胞，这与在手术或放疗前进行的新辅助化疗不同。因此，在预测期内，全球对肿瘤药物的需求预计将增加。

药物的不良反应

化疗药物杀死健康的身体细胞，同时破坏恶性细胞。结果，存在许多个人不想要的副作用。常见的副作用包括皮肤病、脱髮、疲劳、神经病变和骨髓抑制。进一步的阻碍因素包括心臟损伤、红血球数低、疲劳、脱髮、腹泻、体重减轻、肝、肾、肺功能下降、骨骼密度下降以及对化疗药物的普遍忽视。这些都是阻碍市场扩张的因素。

创新技术开发

化疗对于将癌症患者的寿命延长几年至关重要。化疗的最新进展是将药物注射到污染区域来治疗癌症而不伤害健康细胞。该技术已被证明可以去除癌细胞，同时保留健康组织。使用光子雷射器，医疗专业人员可以监测这些奈米颗粒排放到患者体内的情况，并在治疗癌细胞时追踪它们的持续时间和分布。这就是推动该细分市场扩张的原因。

相关成本高

化疗是一种使用药物杀死体内癌细胞或减缓其发展的医疗程序。它是一种典型的癌症治疗方法，可单独使用或与其他治疗方法结合使用。这些药物针对快速分裂的细胞，包括癌细胞和一些健康细胞。不幸的是，正常、健康的细胞也会受到治疗的影响，这可能导致各种负面副作用。由于化疗药物价格高昂，市场扩张预计将缓慢。

COVID-19 的影响：

医疗保健系统受到了 COVID-19大流行的影响，市场也受到了重大影响。这场大流行扰乱了世界各地的药品和医疗用品的分配。这可能导致化疗药物和其他相关医疗用品的交付延迟或短缺。由于大流行，癌症研究和临床试验暂时停止，因为许多研究机构和製药公司专注于开发 COVID-19 的治疗方法和疫苗。这可能推迟了化疗等抗癌药物的开发。

预计在预测期内，口服细分市场将是最大的

预计在预测期内这将是口腔领域最大的一次。用于治疗口腔癌的药物有锭剂、胶囊和液体型态。然而，静脉注射的成长速度最快。静脉注射化疗药物比给药或局部给药化疗药物起效更快，因为它们更快进入循环。

预计白血病细分市场在预测期内将经历最高的复合年增长率。

预计白血病领域在预测期内复合年增长率最高。生长缓慢的白血病可能需要监测作为治疗的一部分。严重白血病的治疗可能包括化疗、放疗和干细胞移植的组合。女性乳癌发病率的增加、可用治疗方法的多样性以及使用最尖端科技改进乳癌诊断都有助于该领域的扩展。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。由于能够根除癌细胞，化疗比其他类型的治疗方法越来越受青睐。该市场是由多家化疗药物製造商的存在和不断增长的医疗保健支出所推动的。该市场也受到医疗设施的便利性以及癌症研究和治疗中最尖端科技的使用的推动。

复合年增长率最高的地区：

预计亚太地区在预测期内将维持最高的复合年增长率。这是政府扩大意识提升倡议和降低该地区医疗成本的结果。由于训练有素且有能力的医疗保健提供者的存在以及对化疗药物不断增长的需求，扩大了仿製药的获取范围，这也导致了该地区市场增长的放缓。政府癌症保险计划预计将推动市场成长。因此，政府支出和癌症发生率上升将推动市场发展。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球化疗市场：依药物分类

  • 介绍
  • 抗肿瘤抗生素
  • 拓朴异构酶抑制剂
  • 烷化剂
  • 有丝分裂抑制剂
  • 抗代谢物
  • 其他药品

第6章全球化疗治疗市场：依药物途径

  • 介绍
  • 静脉
  • 口服
  • 皮下的
  • 血管内的
  • 肌肉注射
  • 腹膜内
  • 局部的
  • 脑室内

第7章全球化疗治疗市场：依适应症分类

  • 介绍
  • 大肠直肠癌
  • 白血病
  • 摄护腺癌
  • 乳癌
  • 胃癌
  • 肉瘤
  • 肺癌
  • 骨髓瘤
  • 卵巢癌
  • 淋巴瘤
  • 其他适应症

第8章全球化疗治疗市场：依最终使用者分类

  • 介绍
  • 医院和诊所
  • 专业中心
  • 研究机构
  • 其他最终用户

第9章全球化疗治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb
  • Schering-Plough
  • Eli Lilly & Company
  • ImClone Systems Inc.
  • Boehringer Ingelheim
  • E. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Chemo Espana SL
  • CELGENE CORPORATION
  • Sanofi
  • Teva Pharmaceuticals Industries
  • Pfizer Inc.
  • Amgen Inc
Product Code: SMRC24218

According to Stratistics MRC, the Global Chemotherapy Market is accounted for $8.81 billion in 2023 and is expected to reach $16.62 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments including surgery, radiation therapy, or immunotherapy. Chemotherapy medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects, including nausea, hair loss, exhaustion, and a weaker immune system.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Cancer incidence has surged internationally, surpassing cardiovascular disease as the second greatest cause of death. Chemotherapy, the most common type of cancer treatment, is commonly coupled with other cancer medicines. Contrary to neo-adjuvant chemotherapy, which is administered prior to surgery and radiation therapy, adjuvant chemotherapy is used to reduce the tumor cell after surgery or radiation therapy. As a result, it is predicted that throughout the projected period, there will be a global increase in demand for oncology cancer medications.

Restraint:

Negative effects of drugs

Chemotherapy drugs kill healthy body cells while destroying malignant cells. This includes a number of unfavourable side effects for the individuals. Some common adverse effects include skin problems, hair loss, tiredness, neuropathies, and bone marrow suppression. A further disincentive will be the adverse effects of chemotherapy drugs, such as heart problems, low red blood cell counts, tiredness, hair loss, diarrhea, weight loss, impaired liver, kidney, and lung function, decreased bone density, and general ignorance. These are the elements limiting the market's expansion.

Opportunity:

Development of innovative technology

Chemotherapy has been essential in extending cancer patients' lives for a few more years than they otherwise would have. The most recent development in chemotherapy involves injecting drugs that treat cancer without hurting healthy cells into polluted regions. It has been demonstrated that using this technique keeps healthy tissue intact while removing cancerous cells. Using photon lasers, medical professionals may monitor the discharge of these nanoparticles into a patient's body and follow their duration and distribution while treating cancerous cells. This is the element propelling the segment's expansion.

Threat:

High associated costs

Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments. These medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects. The high price of the chemotherapy drug will slow the market's expansion.

COVID-19 Impact:

The healthcare systems have been impacted by the COVID-19 pandemic, and the market has also been significantly impacted. The epidemic hampered the flow of drugs and medical supplies around the globe. This might have resulted in delays or shortages in the delivery of chemotherapy medications and other relevant medical supplies. Cancer research and clinical trials were briefly put on hold as a result of the pandemic as many institutes and pharmaceutical corporations concentrated on creating cures and vaccinations for COVID-19. This could have slowed down developments in cancer medicines like chemotherapy.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. A medicine used to treat oral cancer comes in the form of a tablet, capsule, or liquid. The fastest growth rate was, however, seen with intravenous administration. Chemotherapy medications work faster because they are taken into the circulation promptly when given intravenously than when given orally or topically.

The leukemia segment is expected to have the highest CAGR during the forecast period

The leukemia segment is expected to have the highest CAGR during the forecast period. Slow-growing leukemias may require monitoring as part of their therapy. To treat severe leukemias, a combination of chemotherapy, radiation treatment, and stem cell transplantation may be employed. The rising incidence of breast cancer in women, the diversity of treatments available, and enhanced techniques for breast cancer diagnosis employing cutting-edge technology all contribute to the sector's expansion.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Chemotherapy is increasingly being preferred over other types of treatment because of its capacity to eradicate cancer cells. The market is primarily driven by the presence of multiple chemotherapy medication producers and an increase in healthcare spending. The market is also being driven by the accessibility of healthcare facilities and the use of cutting-edge technology in the investigation and treatment of cancer.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a result of expanded government awareness initiatives and g rowing healthcare costs in this area. Due to the availability of trained and competent healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic pharmaceuticals will also help to slow the market's rate of progress in this area. Government cancer insurance programs are anticipated to drive market growth. Government expenditure and a rise in the incidence of cancer will thus drive the market.

Key players in the market

Some of the key players in Chemotherapy market include: AstraZeneca, GlaxoSmithKline, Novartis, Bayer AG, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Schering-Plough, Eli Lilly & Company, ImClone Systems Inc., Boehringer Ingelheim, E. Hoffmann-La Roche Ltd, Merck & Co. Inc., Chemo Espana SL, CELGENE CORPORATION, Sanofi, Teva Pharmaceuticals Industries, Pfizer Inc. and Amgen Inc.

Key Developments:

In October 2023, Novartis present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

In February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.

Drugs Covered:

  • Anti-Tumor Antibiotics
  • Topoisomerase Inhibitors
  • Alkylating Agents
  • Mitotic Inhibitors
  • Antimetabolites
  • Other Drugs

Route of Drugs Covered:

  • Intravenous
  • Oral
  • Subcutaneous
  • Intravascular
  • Intra-Muscular
  • Intraperitoneal
  • Topical
  • Intraventricular

Indications Covered:

  • Colorectal Cancer
  • Leukemia
  • Prostate Cancer
  • Breast Cancer
  • Stomach Cancer
  • Sarcoma
  • Lung Cancer
  • Myeloma
  • Ovarian Cancer
  • Lymphoma
  • Other Indications

End Users Covered:

  • Hospitals & Clinics
  • Specialty Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Chemotherapy Market, By Drug

  • 5.1 Introduction
  • 5.2 Anti-Tumor Antibiotics
  • 5.3 Topoisomerase Inhibitors
  • 5.4 Alkylating Agents
  • 5.5 Mitotic Inhibitors
  • 5.6 Antimetabolites
  • 5.7 Other Drugs

6 Global Chemotherapy Market, By Route of Drug

  • 6.1 Introduction
  • 6.2 Intravenous
  • 6.3 Oral
  • 6.4 Subcutaneous
  • 6.5 Intravascular
  • 6.6 Intra-Muscular
  • 6.7 Intraperitoneal
  • 6.8 Topical
  • 6.9 Intraventricular

7 Global Chemotherapy Market, By Indication

  • 7.1 Introduction
  • 7.2 Colorectal Cancer
  • 7.3 Leukemia
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Stomach Cancer
  • 7.7 Sarcoma
  • 7.8 Lung Cancer
  • 7.9 Myeloma
  • 7.10 Ovarian Cancer
  • 7.11 Lymphoma
  • 7.12 Other Indications

8 Global Chemotherapy Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Specialty Centers
  • 8.4 Research Institutes
  • 8.5 Other End Users

9 Global Chemotherapy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AstraZeneca
  • 11.2 GlaxoSmithKline
  • 11.3 Novartis
  • 11.4 Bayer AG
  • 11.5 Takeda Pharmaceutical Company Limited
  • 11.6 Bristol-Myers Squibb
  • 11.7 Schering-Plough
  • 11.8 Eli Lilly & Company
  • 11.9 ImClone Systems Inc.
  • 11.10 Boehringer Ingelheim
  • 11.11 E. Hoffmann-La Roche Ltd
  • 11.12 Merck & Co. Inc.
  • 11.13 Chemo Espana SL
  • 11.14 CELGENE CORPORATION
  • 11.15 Sanofi
  • 11.16 Teva Pharmaceuticals Industries
  • 11.17 Pfizer Inc.
  • 11.18 Amgen Inc

List of Tables

  • Table 1 Global Chemotherapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Chemotherapy Market Outlook, By Drug (2021-2030) ($MN)
  • Table 3 Global Chemotherapy Market Outlook, By Anti-Tumor Antibiotics (2021-2030) ($MN)
  • Table 4 Global Chemotherapy Market Outlook, By Topoisomerase Inhibitors (2021-2030) ($MN)
  • Table 5 Global Chemotherapy Market Outlook, By Alkylating Agents (2021-2030) ($MN)
  • Table 6 Global Chemotherapy Market Outlook, By Mitotic Inhibitors (2021-2030) ($MN)
  • Table 7 Global Chemotherapy Market Outlook, By Antimetabolites (2021-2030) ($MN)
  • Table 8 Global Chemotherapy Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 9 Global Chemotherapy Market Outlook, By Route of Drug (2021-2030) ($MN)
  • Table 10 Global Chemotherapy Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 11 Global Chemotherapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 12 Global Chemotherapy Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 13 Global Chemotherapy Market Outlook, By Intravascular (2021-2030) ($MN)
  • Table 14 Global Chemotherapy Market Outlook, By Intra-Muscular (2021-2030) ($MN)
  • Table 15 Global Chemotherapy Market Outlook, By Intraperitoneal (2021-2030) ($MN)
  • Table 16 Global Chemotherapy Market Outlook, By Topical (2021-2030) ($MN)
  • Table 17 Global Chemotherapy Market Outlook, By Intraventricular (2021-2030) ($MN)
  • Table 18 Global Chemotherapy Market Outlook, By Indication (2021-2030) ($MN)
  • Table 19 Global Chemotherapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 20 Global Chemotherapy Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 21 Global Chemotherapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 22 Global Chemotherapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 23 Global Chemotherapy Market Outlook, By Stomach Cancer (2021-2030) ($MN)
  • Table 24 Global Chemotherapy Market Outlook, By Sarcoma (2021-2030) ($MN)
  • Table 25 Global Chemotherapy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 26 Global Chemotherapy Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 27 Global Chemotherapy Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 28 Global Chemotherapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 29 Global Chemotherapy Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 30 Global Chemotherapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Chemotherapy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 32 Global Chemotherapy Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 33 Global Chemotherapy Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 34 Global Chemotherapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.